Contemporary Issues in Evaluating Treatment in Neurodevelopmental Disorders

1. Considerations for measuring individual outcomes across contexts in Down syndrome: Implications for research and clinical trials<br>Anna Esbensen, Emily K. Schworer, Deborah J. Fidler, Angie John Thurman<br>2. Remotely Monitoring Development and Treatment Outcomes in Families affected by IDD <br>Bridgette Kelleher, Tyra Protho, Lisa Hamrick, Andrea DeMaria, Carolyn McCormick, Mandy Rispoli, Delta Smith, Jamie Krueger︎<br>3. Psychometric perspectives on developmental outcome and endpoint selection in treatment trials for genetic conditions associated with neurodevelopmental disorder<br>Cristan Farmer, Audrey Thurm, Liz Berry-Kravis, Aaron Kaat<br>4. Evaluating Outcomes within Culturally Diverse Contexts for Children and Youth with Developmental Disabilities<br>Sandra B. Vanegas, Sandy Magana<br>5. Measurement of Social Skills Treatment Outcome in Autism: Moving Beyond Informant Report and Considering Diversity<br>Elizabeth Laugeson, Christine T. Moody, Hillary K. Schiltz, Allison B. Ratto, Amanda Gulsrud<br>6. Cognitive Outcome Measures for tracking alzhiemer’s Disease in Down syndrome<br>Sigan Hartley, Tori Fleming, Christy Hom, Isabel Clare, Sharon Krinsky-McHale, Benjamin Handen, Shemaya Hurd-Thomas<br>7. A Scoping Review of Psychosocial Interventions for Neurogenetic Conditions across the Lifespan<br>Marisa Fisher, Bonita P Klein-Tasman, Allora Mohanty<br>8. Clinical Trials and Outcome Measures: Lessons Learned from Chromosome 15 disorders<br>Jessica Duis<br>9. Well-being and challenging behaviour in people with severe intellectual disability and complex needs: Assessment of causes and evaluation of outcomes of interventions<br>Chris Oliver, Dawn Adams, Georgie Agar, Debbie Allen, Stacey Bissell, Justin Chung, Hayley Crawford, Kat Ellis, Laura Groves, May Heald, Lauren Jenner, Jo Moss, Effie Pearson, Caroline Richards, Rachel Royston, Jane Waite, Alice Welham, Lucy Wilde, Kate Woodcock<br>10. Novel cognitive, language, biophysical and molecular outcomes and response predictors for clinical trials in fragile X syndrome<br>Craig Erickson, David Hessl, Leonard Abbeduto, Anne Hoffmann, Laura Del Hoyo Soriano, Lauren Bullard, Angela John Thurman, Ernest Pedapati, Lauren Ethridge, Christina Gross, Kevin J Sharp, Elizabeth M Berry-Kravis